ArticleActa Cardiologica Sinica2025
Uric Acid to HDL-C Ratio as a Marker of Coronary Artery Disease Severity in Non-ST-Elevation Myocardial Infarction Patients.
Article in Acta Cardiologica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Uric Acid-to-HDL Cholesterol Ratio as an Independent Predictor of In-Hospital New-Onset Atrial Fibrillation in Non-ST-Elevation Myocardial Infarction.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The uric acid-to-high-density lipoprotein cholesterol ratio (UHR) has been associated with both the functional and anatomical significance of coronary lesions. This study aimed to investigate the relationship between UHR and the severity of coronary artery disease (CAD) in patients with non-ST-elevation myocardial infarction (NSTEMI), as evaluated using the Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score. Methods: This retrospective study analyzed data from 606 NSTEMI patients who underwent coronary angiography between April and December 2024. UHR was calculated by dividing serum uric acid by high-density lipoprotein cholesterol. Patients were classified into low (SYNTAX < 23) and intermediate-high severity (SYNTAX ≥ 23) groups and compared in terms of parameters including UHR. Results: UHR showed a significant positive correlation with SYNTAX score (ρ = 0.417, p < 0.001) and emerged as an independent predictor of intermediate-high severity CAD (odds ratio: 1.069, p < 0.001). Receiver operating characteristic curve analysis yielded an area under the curve of 0.705, with a UHR cut-off of > 20.35 predicting intermediate-high severity with 49.5% sensitivity and 85.4% specificity. Left ventricular ejection fraction also independently predicted CAD severity. Conclusions: UHR is an easily measurable, cost-effective biomarker for assessing CAD severity in NSTEMI patients. Its integration into clinical practice may improve early risk stratification and management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.